VKTX Viking Therapeutics, Inc.

+0  (1%)
Previous Close 1.39
Open 1.40
Price To book 3.60
Market Cap 33.59M
Shares 23,825,000
Volume 158,906
Short Ratio 1.72
Av. Daily Volume 158,645

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due late 2017.
Phase 2 to be completed mid-2017.
Acute Hip Fracture

Latest News

  1. Viking Therapeutics to Present at H.C. Wainwright & Co.'s 1st Annual NASH Investor Conference
  2. Viking Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update
  3. Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2016 After Market Close on March 21, 2017
  4. Viking Therapeutics to Present at Upcoming Investor Conferences
  5. VKTX: Successful Preclinical Data for VK2809 in Glycogen Storage Disease 1a
  6. Viking Therapeutics and PoC Capital Enter Agreement to Fund Clinical Development of VK2809 in Glycogen Storage Disease Ia (GSD Ia)
  7. Viking Therapeutics Announces Initial Results from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease Ia (GSD Ia)
  8. Viking Therapeutics to Present at 2017 BIO CEO & Investor Conference
  9. Viking Therapeutics Announces Senior Level Appointments to Management Team
  10. Viking Therapeutics to Present at Biotech Showcase 2017
  11. VKTX: Additional Data Show Promise of VK2809 in Lipid Disorders…
  12. 7 Stocks Under $10 That Could Make You a Lot of Money
  13. VKTX: Encouraging Preclinical Data for VK0214 in Mouse Model of X-ALD
  14. VKTX: Data From Phase 2 Studies of VK2809 for Hypercholersterolemia and VK5211 for Hip Fracture to be Reported in 2Q17
  15. Here’s Why Investors Are Watching Caterpillar, Sensata Technologies & Three Other Stocks
  16. Viking Therapeutics Gets Positive Top-Line Results From Proof-Of-Concept Trial Of VK0214
  17. VKTX: Phase 2 Study of VK5211 for Hip Fracture Ongoing; Phase 2 Study of VK2809 for Hypercholersterolemia to Commence in mid-2016
  18. 5 Stocks Under $10 Set to Soar Higher
  19. VKTX: Positive Phase 1b Data Presented for VK2809 in Hypercholestermic Patients; Recent M&A Activity Shows Viking is Significantly Undervalued
  20. Viking Therapeutics (VKTX) Stock Rising on Positive Clinical Results